+6,019.4%
NVDA vs MRNA
+516.4%
+5,503.0%
-66.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.9% | -3.4% | +2.5% | -0.7% |
| 7D | -0.3% | -10.1% | +9.7% | +0.4% |
| 30D | +2.8% | +126.7% | -123.9% | -9.9% |
| 3M | +7.4% | +184.1% | -176.7% | -9.7% |
| 6M | +22.6% | +143.3% | -120.7% | +4.9% |
| YTD | +20.1% | +359.9% | -339.8% | -6.9% |
| 1Y | +31.2% | +454.2% | -423.0% | -2.1% |
| 3Y | +391.7% | +26.0% | +365.7% | +331.5% |
| 5Y | +911.9% | -70.3% | +982.1% | +889.2% |
| All | +6,019.4% | +516.4% | +5,503.0% | +4,236.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling